MOG and myeloid sarcoma: Similarly, the pathology of CNS lesions in MOGAD verifies the unique nature of the disease: although some similarities to type-II MS pattern demyelinating lesions have been described, there is prominent complement deposition and preservation of pre-oligodendrocytes that do not express MOG [94,95,96,97,98].